Results 11 to 20 of about 12,396 (213)

Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity. [PDF]

Diabetes Ther
Precision diabetology is increasingly becoming diabetes phenotype-driven, whereby the specific hormonal imbalances involved are taken into consideration.
Volčanšek Š, Koceva A, Jensterle M, Janež A, Muzurović E.   +4 more
europepmc   +2 more sources

Amylin – Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity

Molecular Metabolism, 2018
Background: Amylin is a pancreatic β-cell hormone that produces effects in several different organ systems. One of its best-characterized effects is the reduction in eating and body weight seen in preclinical and clinical studies.
Christina Neuner Boyle, Thomas Alexander Lutz   +1 more
exaly   +3 more sources

Amylin in the Periphery [PDF]

The Scientific World Journal, 2003
Amylin (islet amyloid polypeptide) is a peptide synthesized principally in the b-cells of the pancreatic islets together with insulin and has actions as a hormone, growth factor, and modifier of behavior.
Peter J. Wookey, Loredanna Xuereb, Christos Tikellis, Mark E. Cooper   +3 more
doaj   +4 more sources

Amylin exacerbates tau pathology in the visual cortex of diabetic mice by impairing lysosomal activity [PDF]

Genes and Diseases
The aggregation of the peptide hormone amylin in the pancreas is a pathological hallmark of type-2 diabetes. Additionally, amylin can form aggregates in the brain, promoting β-amyloid deposition and tau phosphorylation in Alzheimer's disease.
Daniel Moreira-Silva, Melike Yuksel, Moorthi Ponnusamy, Mitchell T. Hansen, Joseph D. McMillan, Sneha Geethakrishnan, Shuai Wang, Lisa A. Collier, Gopal Thinakaran   +8 more
doaj   +2 more sources

Amylin inhibits gastric cancer progression by targeting CCN1 and affecting the PI3K/AKT signalling pathway [PDF]

Annals of Medicine
Background: After glucagon and insulin, amylin is the third most significant and active islet hormone. Amylin and insulin act synergistically to suppress postprandial blood glucose levels.
Li Liu, Wenxuan Liu, Wenhong Deng
doaj   +2 more sources

Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity [PDF]

Journal of Obesity & Metabolic Syndrome
Amylin is a pancreatic peptide hormone that regulates blood glucose levels and appetite. This review outlines the physiological role of amylin and highlights recent clinical studies exploring its therapeutic potential in diabetes and obesity.
Chae Won Chung, Jaetaek Kim
doaj   +2 more sources

Amylin Receptor 1 Mutagenesis Revealed a Potential Role of Calcitonin Serine 29 in Receptor Interaction [PDF]

Biomedicines
Background: The amylin receptor is a receptor for the peptide hormone amylin, and its activation is known to reduce body weight. The amylin receptor functions as a heterodimer complex that consists of the calcitonin receptor for peptide hormone ...
Hyeseon Song, Jaehyeok Jang, Minjae Park, Junsu Yun, Jeongwoo Jin, Sangmin Lee   +5 more
doaj   +2 more sources

A cationic polymethacrylate-copolymer acts as an agonist for β-amyloid and an antagonist for amylin fibrillation

Chemical Science, 2019
This study demonstrates the modulation of amyloid aggregation of two human proteins, amyloid-beta and amylin, by a cationic polymer (PMAQA).
Bikash Sahoo, Toshio Ando, Ayyalusamy Ramamoorthy   +2 more
exaly   +2 more sources

Detection of Amylin-β-amyloid Hetero-Oligomers by Enzyme-Linked Immunosorbent Assay [PDF]

Bio-Protocol
Amylin is an amyloidogenic neuroendocrine hormone co-synthesized and co-secreted with insulin from the pancreas. It readily crosses the blood–brain barrier and synergistically forms mixed amyloid plaques with β-amyloid (Aβ) in brain parenchyma ...
Noah Leibold, Deepak Kotiya, Nirmal Verma, Florin Despa   +3 more
doaj   +2 more sources

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. [PDF]

Diabetes Obes Metab
Abstract Aim Eloralintide (LY3841136) is a potent, long‐acting selective amylin receptor agonist currently under development for the treatment of obesity with once‐weekly subcutaneous dosing. Materials and Methods This 12‐week Phase 1, randomised, placebo‐controlled, participant‐ and investigator‐blinded, multiple ascending dose study evaluated the ...
Bhattachar S, Tham LS, Tidemann-Miller B, Ibriga H, Qu H, Briere DA, Haupt A, Mather KJ, Pratt E.   +8 more
europepmc   +2 more sources